Concerns about Elon Musk’s alleged drug use are causing unease among executives and board members overseeing the companies he leads, according to a Wall Street Journal report.
Anonymous sources familiar with Musk and his businesses indicate continued use of ketamine, despite Musk saying last August that he had a prescription for the drug as an antidepressant.
The report outlines Musk’s history of alleged consumption of LSD, cocaine, ecstasy and psychedelic mushrooms, mostly in private gatherings.
In response to the claims, Musk’s lawyer emphasized that the billionaire undergoes regular and random drug tests at SpaceX and consistently passes no problems.
Musk’s public use of marijuana alongside podcaster Joe Rogan in 2018 prompted a Pentagon review of his federal security clearance due to his role as CEO of SpaceX.
Also read: SFJ blocks Indian consulate in San Francisco with Indira Gandhi float
Elon Musk addressed the allegations on X (formerly Twitter), stating: “After that one cover with Rogan, I agreed to do 3 years of random drug testing at NASA’s request. No trace amounts of any drugs or alcohol were found. “
The report further suggested that Linda Johnson Rice, Tesla’s director since 2017, decided not to seek re-election due to frustration with Musk’s behavior and alleged drug use.
Elon Musk oversees a diverse portfolio of six companies: Tesla, SpaceX, X (formerly Twitter), The Boring Co., Neuralink and xAI, an artificial intelligence startup. The revelation of Musk’s alleged drug use adds a layer of scrutiny to the entrepreneur’s leadership in these businesses.
